COMP <GO>
AVLN vs AMPH // EV/EBITDA & P/E VALUATION
Avalyn Pharma Inc. (NASDAQ) VS. Amphastar Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: AVLN 0
— AMPH 2
■ METRIC PARITY
LAST: $25.71 (-0.12%) • MKT CAP: $1.14B
valuation
—
LAST: $26.93 (+2.28%) • MKT CAP: $1.15B
valuation
9.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AVLN VS. AMPH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AVLN | AMPH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 49.50% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | 9.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 9.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 10.58% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | 19.50% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 13.60% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -1.70% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 2.47 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 7/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.2 | 66.8 | -22.64 | AMPH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 10.9x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.14B | $1.15B | -$5.7M | AMPH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AVLN REV | AMPH REV | AVLN GROSS % | AMPH GROSS % | AVLN FCF | AMPH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $719.9M | — | 49.5% | — | $121.2M |
| FY 2024 | — | $732.0M | — | 51.1% | — | $172.3M |
| FY 2023 | — | $644.4M | — | — | — | $183.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AVLN // BETA —
AMPH // BETA —